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Abstract
Background: The monoclonal antibody natalizumab (NAT) inhibits the migration of lymphocytes throughout the
blood–brain barrier by blocking very late antigen (VLA)-4 interactions, thereby reducing inflammatory central
nervous system (CNS) activity in patients with multiple sclerosis (MS). We evaluated the effects of different NAT
treatment regimens.
Methods: We developed and optimised a NAT assay to measure free NAT, cell-bound NAT and VLA-4 expression
levels in blood and cerebrospinal fluid (CSF) of patients using standard and prolonged treatment intervals and after
the cessation of therapy.
Results: In paired CSF and blood samples of NAT-treated MS patients, NAT concentrations in CSF were approximately
100-fold lower than those in serum. Cell-bound NAT and mean VLA-4 expression levels in CSF were comparable
with those in blood. After the cessation of therapy, the kinetics of free NAT, cell-bound NAT and VLA-4 expression
levels differed. Prolonged intervals greater than 4 weeks between infusions caused a gradual reduction of free
and cell-bound NAT concentrations. Sera from patients with and without NAT-neutralising antibodies could be
identified in a blinded assessment. The NAT-neutralising antibodies removed NAT from the cell surface in vivo
and in vitro. Intercellular NAT exchange was detected in vitro.
Conclusions: Incorporating assays to measure free and cell-bound NAT into clinical practice can help to
determine the optimal individual NAT dosing regimen for patients with MS.
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Background
Natalizumab (NAT, Biogen Idec) is a monoclonal IgG4
antibody approved for the treatment of highly active
relapsing remitting multiple sclerosis (MS) [1]. Blockade
of the interaction between very late antigen (VLA)-4
and vascular cell adhesion molecule (VCAM)-1 at the
blood–brain barrier (BBB) reduces the transmigration of
leukocytes into the brain, which reduces inflammatory
lesions in MS patients [2]. It also has a negative impact
on central nervous system (CNS) immunosurveillance,
which is responsible for development of progressive
multifocal leukoencephalopathy (PML) [3, 4].
The pharmacokinetics and pharmacodynamics of free
NAT and the immunological effects of VLA-4 blockade
on peripheral immune cells are well known [5–9], but
there is little information on the pharmacology beyond
the BBB [10]. In addition, only limited information is
available about the pharmacokinetics and pharmaco-
dynamics of NAT metabolism after patients stop treat-
ment or if they are treated with NAT infusion intervals
longer than 4 weeks [8, 11, 12]. These questions are
starting to be explored, and treatment strategies that ad-
just the NAT dose to the patient’s body weight are being
adopted [13]. There also is interest to determine NAT
pharmacokinetics and pharmacodynamics in patients
with MS who switch to other treatments [14].
To quantify free and cell-bound NAT peripheral blood
and CSF, we developed a new immunological assay using
fluorescence-activated cell sorting (FACS) analysis. Here,
we applied this new assay to in vitro experiments on the
exchange of cell-bound NAT with NAT-neutralising
antibodies (NABs) and to monitor different clinical sce-
narios. We determined the NATcharacteristics in patients
stopping NAT treatment and patients with different
infusion intervals. The effects of NAT-neutralising
antibodies were investigated using 30 blinded sera of
NAT-treated patients.
Methods
Subjects
To analyse free and cell-bound NAT, paired CSF and
blood samples of 27 MS patients receiving monthly NAT
treatment and 24 untreated MS patients were obtained
(Table 1A). All patients were prospectively documented
in the NAT module of MSDS software [15] and were
stable for at least 12 months before the study. A total of
13 patients receiving NAT therapy were reevaluated after
12 monthly NAT infusions. No NAT-treated patient ex-
hibited clinical disease symptoms. One patient who was
positive for NAT-neutralising antibodies was analysed
separately. Blood samples were obtained immediately
before and 20 min after NAT infusion, whereas CSF
was only obtained immediately before NAT infusion. To
evaluate the effects of different infusion intervals on free
NAT concentration, we obtained sera of 46 MS patients
that were stable for more than 6 months on the following
NAT infusion intervals: 4 weeks (n = 18), 5 weeks (n = 18),
and 8 weeks (n = 10). CSF was collected only from pa-
tients who volunteered for a lumbar puncture (Table 1B).
To analyse the effect of NAT cessation, blood samples of
18 MS patients who received a mean of 34.8 ± 16.1 NAT
infusions were obtained 20 min after their last NAT infu-
sion and monthly during the NAT washout period for up
to 4 months (Table 1C). Patients were monitored for oc-
currence of confirmed clinical relapses and of Gadolinium
enhancing (GdE) or new T2 lesions in magnetic reson-
ance imaging (MRI). The study procedure was performed
according the Declaration of Helsinki and the study
protocol was approved by the Ethics Committee of the
Faculty of Medicine of the Dresden University of Techno-
logy. All participants provided informed written consent.
Methods
To measure free NAT concentration, serum samples
(dilution 1:100 to 1:750), CSF samples (undiluted) and
standard solutions with different NAT concentrations
(between 10−4 and 10 μg/ml) were added to 96-well
plates containing HL60 cells. Cells were stained with
anti-IgG4 antibody (Southern Biotech). Mean fluores-
cence intensity (MFI) was analysed using FACS (FACS
Calibur, BD Biosciences). A NAT standard curve was
generated in triplicate based on the MFI of standard
concentrations (Additional file 1: Figure S1). The mini-
mum calculated detection limit was 14 ng/ml. Intra-
assay and inter-assay reliability was consistently below
5 and 10 %, respectively. Antibody specificity was tested
Table 1 Subject characteristics
(A) Standard treatment interval (B) Extended treatment intervals (C) Cessation
NAT Non-NAT 4 weeks 5 weeks 8 weeks
Number of patients 27 24 18 18 10 18
Women (%) 60 70 50 72 67 61
Age in years (mean ± SD) 35.4 ± 9.4 38.5 ± 12.1 36.9 ± 9.4 44.8 ± 6.7 42.7 ± 8.5 38.3 ± 10.2
Years of disease (mean ± SD) 8.9 ± 6.8 1.4 ± 4.6 8.9 ± 6.8 14.5 ± 7.5 10.0 ± 3.0 10.4 ± 8.3
EDSSa (mean ± SD) 3.5 ± 1.6 2.5 ± 1.6 3.5 ± 1.6 3.7 ± 1.1 3.3 ± 1.53 3.7 ± 1.9
aEDSS, Kurtzke Expanded Disability Status Scale
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using an anti-NAT-neutralising antibody. For NAT satu-
ration and VLA-4 expression, cells were stained ex vivo
using CD45 (Dako) and CD3 primary antibodies and
anti-CD49d (BD Biosciences) and anti-IgG4 secondary
antibodies, respectively. Positive (in vitro maximum-
loaded frozen samples), negative (untreated frozen cells)
and anti-IgG3 (Southern Biotech) isotype controls were
co-analysed. Label saturation was defined as the MFI
difference between cells labelled with the anti-IgG4 and
anti-IgG3 isotypes.
Cells were analysed as follows. CSF samples were cen-
trifuged within 20 min after collection. Peripheral blood
mononuclear cells were isolated from the heparinised
blood samples using Biocoll separating solution (Biochrom
Ag) and Ficoll-Paque (Amersham Biosciences) in Leuco-
Sep tubes (Greiner Bio One). Plasma and serum super-
natants were collected and frozen for subsequent NAT
concentration analysis.
To evaluate NAT-dependent VCAM binding, specific
dilutions of NAT or biological material (serum and CSF)
were added to HL60 cells. Then, VCAM-IgG1 His-Tag
Chimera (R&D Systems) was added to cells. Cells were
stained with anti-IgG4 and anti-His-Tag (Lifespan Bio-
sciences) antibodies and then analysed by FACS.
For in vitro analysis of intercellular NAT exchange,
NAT-loaded and non-loaded carboxyfluorescein succini-
midyl ester (CSFE)-marked HL60 cells were cocultured
for 24 h at 37 °C either mixed at 1:1 ratio or separated
by a permeable membrane (pore size 0.4 μm, Millipore
Transwell). Then, HL60 cells were analysed for IgG4 MFI
mean by FACS and compared with separately cultured
control cells.
A blinded analysis was performed using 30 sera of
NAT-treated patients with or without NABs (provided
by Dr. Gold and Dr. Chan, from the German NABs
laboratory in Bochum, Germany). Different sample di-
lutions of sera were added to the HL60 cells, and the
resulting MFI mean of cell-bound NAT was analysed by
FACS. In a second experiment, dilutions of serum sam-
ples containing NABs were added to standardised NAT
concentrations (used to generate the standard curve).
The resulting MFI mean of anti-IgG4 binding was com-
pared with that of the standard curve.
To investigate the effect of NABs on cell-bound NAT
in vitro, maximally NAT-loaded HL60 cells were incu-
bated with different dilutions of serum containing NABs
for different time intervals. Then, cell-based and free
NAT were measured in the supernatant. Data are
expressed as mean values with standard error of the
mean or standard deviation. Correlations were analysed
using Spearman’s rank correlation coefficients. Wilcoxon’s
matched pair test was used to analyse pre-infusion and
post-infusion differences or other paired analyses. The
unpaired t test or the Mann–Whitney test was used for
other group comparisons. p < 0.05 was considered as sta-
tistically significant. All statistical analyses were performed
using Graph Pad Prism 5.
Results
Free NAT levels are 100-fold lower in CSF relative to
serum
Mean free NAT serum concentration was 18.5 μg/ml
(SD ± 15.3) before NAT infusion and 86.3 μg/ml (SD ±
31.3) immediately after NAT infusion, which represents
an increase of approximately 4.7 times (Fig. 1a). For CSF,
the mean free NAT concentration in CSF was 44.8 ng/ml
(SD ± 41.4) (Fig. 1b). Although there were high inter-
individual variabilities, patients with high NAT levels
pre- and post-infusion at time point one displayed com-
parable pre- and post-infusion levels at time point two
(after having received 12 more NAT infusions) with a
correlation coefficient of r = 0.86 (p < 0.0001) (Additional
file 2: Figure S3). No significant differences were observed
in mean free NAT concentration between the two time
points. During the first and second years, no free NAT
was detected in the CSF or serum of 4/27 and 1/13
patients, respectively, and in all CSF specimen of the
untreated control group.
Free and cell-bound NAT in blood and CSF show different
kinetics in blood and in CSF
The relative MFI of NAT on the cell surface before NAT
infusion was comparable in CSF (3.653, SD ± 1700) and
blood (3.375, SD ± 1545) for all NAT-treated patients
(Fig. 1c, d), whereas untreated controls had low MFI in
CSF and blood (322 and 710). The MFI after one NAT
infusion increased approximately 1.4 times, which was
lower than the observed increase in free NAT. We did
not detect any significant differences in these values
during 1 year of treatment.
VLA-4 expression is reciprocally regulated in blood and
CSF, compared to cell-bound NAT
The relative VLA-4 amount on the cell surface before
NAT infusion was comparable in CSF (756, SD ± 376)
and blood (794, SD ± 426) for all NAT-treated patients
(Fig. 1e, f ). The VLA-4 MFI after a single NAT infusion
was approximately 1.3 times lower than that before infu-
sion. Controls showed much higher VLA-4 expression
levels. The CSF-to-serum ratios of albumin and IgG
concentrations were significantly correlated (r = 0.74,
p < 0.0001) with the CSF-to-serum ratio of free NAT
(r = 0.44, p < 0.057), suggesting that the free NAT dis-
tribution was dependent on free diffusion and blood–
brain barrier damage (such as albumin or IgG). We
found that free and cell-bound NAT in blood and CSF
were significantly correlated (r = 0.49, p < 0.0014 and r =
0.47, p < 0.023), which likely represents a steady state
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between free and cell-bound NAT (Additional file 3:
Figure S2). One patient with NAT-neutralising anti-
bodies had similar values (free and cell-bound NAT and
VLA-4 expression) as those of the untreated control
patients (data not shown).
Free and cell-bound NAT as well as VLA-4 in patients after
NAT cessation and different infusion intervals
After NAT cessation, we measured exponential decreases
of free NAT levels in the peripheral compartment of 67.2,
90.3, 98.6 and 99.9 % from weeks 4, 8, 12 and 16 after the
last drug administration compared to baseline NAT levels
in the same patients (Fig. 2a). NAT was detectable in 6 of
7 patients after 12 weeks after the last infusion, and in 7
of 9 patients 16 weeks after the last infusion. Cell-bound
NAT decreased by 33.6, 55.9, 94.4 and 99.3 % from weeks
4, 8, 12 and 16 after last infusion compared with baseline
levels in the same patients compared to the more gradual
decline in free NAT levels in the same patients (Fig. 2b).
By 12 weeks after the last infusion, no significant differ-
ence in IgG4 binding was detected compared with that of
the control group. VLA-4 expression displayed a slow in-
crease after NAT cessation of 2.8, 24.2, 35.5 and 85.5 % by
4, 8, 12 and 16 weeks after the last infusion. At 16 weeks,
VLA-4 expression was less than 50 % of that of the con-
trol group (Fig. 2c).
Reductions in cell-bound and free NAT and increases in
VLA-4 expression are clinically linked to the recurrence
of disease activity. One third of the patients presented
clinically confirmed relapses whereas nearly two thirds
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Fig. 1 Free NAT, cell-bound NAT and VLA-4 expression levels in regular NAT-treated patients. Free NAT concentration (a, b), cell-bound NAT on
CD3 cells (c,d) and VLA-4 expression level in CD3 cells (e,f) of NAT-treated (NAT; black circle) and untreated (non-NAT; black triangle) patients with
MS were determined in blood (left) and CSF (right). One year later (after 12 more NAT infusions), 13 NAT-treated patients with MS were re-analysed
(NAT + 1a; black square). NAT values in blood were determined before (NAT Pre) and 20 min after (NAT Post) NAT infusion. **p < 0.01, ***p < 0.001
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showed new lesions in MRI (80 % GdE lesions). We still
detected very low NAT concentrations in CSF samples
months after the cessation of NAT treatment (Fig. 2d). In
treatment groups that received NAT infusions every 4, 5
or 8 weeks, significantly higher mean free NAT concen-
trations were detected in patients with 4-week intervals
(22.69 ± 8.37 μg/ml) than in patients with 5-week (15.84 ±
7.58 μg/ml) and 8-week (2.49 ± 0.46 μg/ml) intervals
(Fig. 2e). After infusion, the NAT concentration was sig-
nificantly lower in the 8-week interval group (63.95 ±
11.75 μg/ml) than in the 4-week (92.11 ± 13.3 μg/ml) and
5-week (82.36 ± 14.72 μg/ml) interval groups (Fig. 2e).
These results suggest a higher binding capacity for free
NAT after longer intervals between infusions. In the CNS
compartment, the NAT concentration was significantly
higher in the 4-week (49.26 ± 13.36 ng/ml) than in the
5-week (28.97 ± 21.95 ng/ml) treatment interval groups
(Fig. 2f). None of the patients in any of the three treat-
ment groups displayed any clinical activity of MS disease
symptoms during the investigated time period.
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Functional assay of VCAM-1 binding effects in vitro
To understand the relationship between free and cell-
bound NAT and the lymphocyte count in blood and CSF,
we performed in vitro experiments and added different
NATconcentrations to specific numbers of cells to simulate
the cellular concentration in CSF or blood compartment
(5 or 1000 cells/μl, respectively). To evaluate the functional
VLA-4 activity blocked by NAT, we measured VCAM-1
binding activity and cell-bound NAT. The addition of
increasing NAT concentrations caused a dose-dependent
decrease of functional VCAM-1-binding (Fig. 3a). To
confirm this result, we used different cell numbers with
constant NAT concentrations and observed an increase
of cell-bound NAT and a decrease of VCAM-1-binding
with decreasing cell quantities (Fig. 3b). CSF and serum
samples of several NAT-treated patients were tested,
and functionally active NAT was detected ex vivo illus-
trated by decreasing VCAM-1 binding (Fig. 3c). We de-
tected maximally loaded cells in vitro using cell counts
similar to those in vivo in CSF and blood.
There was a significant correlation between cell-bound
NAT and the ratio of free NAT concentration in CSF
and the cell count (Fig. 3d). To understand potential
exchange between the different NAT pools, we per-
formed co-cultivation experiments using NAT-loaded,
CSFE-labelled cells cultivated with unloaded and un-
labelled cells for 24 h (Fig. 3e). The results showed that
there was a quick and complete exchange of cell-bound
NAT between labelled and unlabelled cells. Then, we
separated both cell groups by a NAT-permeable mem-
brane, and still detected significant but incomplete NAT
exchange. These results indicate that cell-cell contact
enables quick and complete NAT exchange, whereas
only limited exchange of NAT occurs without cell-cell
contact. Cell-bound NAT appears to serve as a NAT
reservoir.
NAT-neutralising antibodies remove cell-bound NAT in
vitro
The cellular effects of NAT-neutralising antibodies were
evaluated in blinded experiments by incubating HL60
cells with serum samples from patients that were posi-
tive or negative for NAT antibody (15 serum samples for
each). In these blinded experiments, all different sam-
ples were correctly identified as either NAB-positive or
NAB-negative cell reactions. First, in the presence of
serum containing NAT-neutralising antibodies, no in-
crease in cell-bound NAT was detected (Fig. 4a). Second,
adding different dilutions of serum containing NAT-
neutralising antibodies to HL60 cells incubated with
standard NAT dilutions causes a release of cell-bound
NAT from the cells. We measured a reduction in the
MFI means of anti-IgG4 binding, and the standard curve
was shifted to different degrees (Fig. 4b).
The next in vitro experiment showed that NAT-
neutralising antibodies neutralised or released cell-
bound NAT. We incubated maximally NAT-loaded
HL60 cells with serum containing NAT-neutralising
antibodies to simulate in vivo NAT concentrations with
respect to cell counts. The results showed that there was a
decrease in cell-bound NAT within the first minutes and a
complete loss within 3 h. This effect was dose-dependent
(Fig. 4c). The removed NAT appeared to form a complex
with the NAT-neutralising antibodies, as our assay did not
detect free NAT in the supernatants. Longitudinal analysis
of a patient who developed NAT-neutralising antibodies
showed the characteristic effects on VLA-4, free NAT
and cell-bound NAT. Before the occurrence of NAT-
neutralising antibodies, increases in free and cell-bound
NAT and a decrease in VLA-4 expression were detected
after starting NAT treatment. After developing NAT-
neutralising antibodies, the opposite effects were observed
(decreases in free and cell-bound NAT and an increase
in VLA-4 expression). These reaction parameters could
be used as markers for in vivo monitoring of NAT-
neutralising antibodies in patients with MS (Fig. 4d).
Discussion
Quantification of free NAT, cell-bound NAT and VLA-4
expression levels may provide a better understanding of
the underlying mechanisms and management of NAT ther-
apy. In this study, we developed a highly sensitive FACS
assay to measure NAT concentrations in CSF. We evalu-
ated the assay using a cell line that has high expression of
VLA-4, anti-IgG4 antibodies and a specific, highly active
anti-NAT-neutralising antibody and showed that the assay
had low inter-assay and intra-assay variability for quantifi-
cation of free and cell-based NAT in CSF and blood.
We found that NAT was detectable in the CSF of pa-
tients who received long-term NAT therapy, which was
consistent with a recent report [10]. In contrast with that
trial, we only included patients who received NAT infu-
sions every 4 weeks, and we determined CSF and serum
NAT levels immediately before NAT infusion, which may
explain the differences in measured NAT levels in the
former and current studies. Harrer et al. reported that the
NAT concentration in the CSF was more than 400 times
lower than that in serum [10]. This result is consistent
with the concept of the CSF as an ultrafiltrate of plasma,
which allows proteins with a hydrodynamic radius smaller
than 500 nm to penetrate the CNS compartment. The
NAT concentrations may be higher in patients with dam-
age to the BBB. We found a close correlation between the
CSF-to-serum ratios of NAT, albumin and IgG. However,
we did not detect any correlation between infusion num-
ber and NAT concentration in our patient cohort, and
there were no significant differences between serum and
CSF NAT concentrations in a subgroup of NAT-treated
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patients that was analysed 1 year later. We detected large
inter-individual variability of NAT levels in serum and
CSF, similar with previous reports [10, 16–18].
We also found that there was a much more pronounced
decline in free NAT levels during a 4-week interval than
cell-bound NAT.
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The presence of NAT in the CNS immune compartment
may have important implications because the functional
properties of T cells that migrate to the CNS could be
modulated in the same way as previously described for
peripheral blood [19–21]. Our in vitro and ex vivo ex-
periments indicate that CSF-localised NAT is func-
tional. Although NAT is mainly active by inhibiting
migration via the blood–brain barrier [22], there is
potential role for functional NAT in the CSF compart-
ment as T cells are still present in the CSF [23]. In con-
trast to Schneider-Hohendorf et al. who described the
lack of VLA-4 of CSF T cells in NAT-treated patients
[24] we could clearly demonstrate cell-bound NAT on
the surface of the remaining CSF T cells using our assay
to detect cell-bound NAT. The binding of VLA-4 to
the sVCAM binding was blocked by NAT binding to
VLA-4 [25]. The possible VLA-4 blockade of CSF T
cells by functional NAT in the CSF may be relevant for
inhibiting their further intraparenchymal migration to
the inflammatory lesion site as VLA-4 mediates cell-
extracellular matrix interaction via, e.g., fibronectin or
osteopontin [26, 27] and may perpetuate the inflam-
matory cascade within the brain parenchyma [28]. The
VLA-4-fibronectin interaction also acts as a costimulatory
or second signal (in addition to T cell receptor signalling)
for lymphocyte proliferation and activation [29]. Al-
though NAT concentration in the CSF was much
lower than those in blood, the amount of NAT that is
bound to the cell surface was comparable in blood and
CSF due to the lower cell count in CSF.
We investigated different NAT-dosing intervals in
addition to the standard interval of 4 weeks. All patients
continuously treated with infusion intervals of 5 or
8 weeks were stable on clinical and MRI monitoring.
However, NAT concentration continuously declined in
CSF and serum when the NAT-dosing interval was lon-
ger than 8 weeks. Combining free and cell-bound NAT
assessments, our assay may provide a unique tool for
the analysis of individual NAT-dosing regimens to iden-
tify the lowest NAT dose that still provides optimal ef-
ficacy. Prior studies have also identified a relationship
between patient weight and NAT. A decrease in dose
adapted to the pharmacodynamics effect of NAT may
lower the PML risk in NAT-treated patients as it has
been proposed for two recently described clinical co-
horts on prolonged NAT-dosing intervals [30, 31]. The
number of patients included in this study was not high
enough to individually link clinical efficacy and free
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respectively cell-bound NAT concentration. However,
we observed more pronounced differences between
pre- and post-dosing NAT concentrations with longer
infusion intervals, suggesting that individualised doses
applied every 4 weeks may have greater benefits of a
constant and dose-adapted pharmacodynamic effect of
VLA-4 blockade than longer individual infusion inter-
vals with a fixed dose.
Monitoring the cessation of NAT treatment revealed
different kinetics of free and cell-bound NAT. Free NAT
levels decline rapidly, whereas the pharmacodynamically
relevant changes of cell-bound NAT and VLA-4 expres-
sion take significant longer time to return to baseline.
The link between pharmacodynamics and the return of
disease activity has already been previously described
[32–34]. Elimination of monoclonal antibodies is gene-
rally slow and involves mechanisms that differ among
patients. Rispens et al. reported that rebound disease ac-
tivity occurred later in patients who showed the highest
NAT levels [18]. Another important clinical argument
for measuring free and cell-bound NAT, especially in
CSF, is the determination of when to start alternative
treatments in patients switching from NAT [35].
Our in vitro experiments demonstrated that there is a
quick cell-to-cell exchange of NAT antibody. Ex vivo
and in vitro results showed that cell-bound NAT can
serve as a NAT reservoir. In in vitro experiments, free
NAT was not detectable until all cells were maximally
loaded. Our blinded experiment could correctly identify
all NAB-positive and NAB-negative patients. In contrast
to the results of Pilz et al. [36], we could detect signifi-
cant effects of NAT loading in all of our NAB-positive
patients. Our analysis of NAB-positive patients indicated
that presence of NAB reduced free NAT levels and was
even able to remove cell-bound NAT from the VLA-4
receptor. In addition, the area under curve serves as a
quantitative functional estimate of the titer and potency
of NAT-neutralising antibodies as differences regarding
the magnitude of the effect could be described for in-
dividual patients. Up to now, only enzyme-linked im-
munosorbent assay (ELISA) and radioimmunoassay
(RIA) analysis is available for the detection of NAB
which cannot describe the functional effects of NAB
in comparison to our assay [37–39]. Further analysis
and improvements are necessary to develop our test
for the evaluation of NAB titer (quantity of NAB) and
potency (ability to remove cell-bound NAT).
This effect of NAT removal by NAB occurred in a dose-
dependent manner within a few hours. Such effective
NAB could theoretically be used to remove NAT from the
cell surface if, for example, PML would have been diag-
nosed. This would be a much more effective and faster
alternative to plasma exchange which can accelerate NAT
clearance only by an average of 92 % within 1 week [7].
Conclusions
Our results suggest that it is important to include free
and cell-bound NAT concentrations in addition to VLA-
4 saturation and functional migration assays in future
studies to link immunology and clinical outcomes for
NAT treatment. Cell-bound NAT and VLA-4 saturation
could be important surrogate markers for NAT efficacy
to identify optimal doses for each patient [8, 40]. These
parameters could be used to optimise an individual dos-
ing regimen and determine the best time to start an al-
ternative treatment after the cessation of NAT therapy.
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Additional file 1: Figure S1. Standard curve of NAT assay. Specific
numbers of HL60 cells were incubated with defined NAT concentrations
and produced repeatable mean fluorescence intensity (MFI). These values
were used to create a standard curve for NAT concentration (connected
line). Specificity was tested using NAT-neutralising antibodies of a
NAT-treated patient with multiple sclerosis (resulting value white circle).
(PPTX 112 kb)
Additional file 2: Figure S3. Correlation of pre- and post-serum values
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NAT serum values at timepoint 0 and after 1 year (+1a). r = Spearman’s rank
correlation coefficient, p = p value of significance. (PPTX 45 kb)
Additional file 3: Figure S2. Correlation of CSF and serum values in
the blood–brain barrier. Correlations of serum and CSF values for free
NAT concentration (A) or cell-bound NAT MFI (B). Correlations of CSF-
to-serum ratios of albumin concentration (C) or IgG concentration (D)
with the CSF-to-serum ratio of free NAT concentration. Values from NAT-
treated patients with MS (black circle) who were partly reevaluated after
1 year (black square). r = Spearman’s rank correlation coefficient, p = p value
of significance. (PPTX 270 kb)
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